Download clinical trials

Studies Open for recruitment at Johns Hopkins Singapore
last updated: 24-Mar-16
Liver Cancer
Main Criteria
Study title
Any HCC
National Registry of Hepatocellular Carcinona
2nd line
Protocol XL184-309: A Phase 3, Randomized, Double-blind,
Controlled Study of Cabozantinib (XL184) vs Placebo in
Subjects with Hepatocellular Carcinoma Who Have
Received Prior Sorafenib
Specification
Principal Investigator
Study information website
SC, contact
Prof. Alex Chang
Not applicable
Xiaoying, 96446688
CHILD-PUGH A, after sorafenib
failed, must has histological or Dr. Akhil Chopra
cytological diagnosis of HCC
http://www.clinicaltrials.gov/ct2/show
/NCT01908426?term=Cabozantinib+% Ruth, 96421767
28XL184%29&rank=7
https://clinicaltrials.gov/ct2/show/NCT
02576509?term=A+Randomized%2C+
Multicenter+Phase+III+Study+of+Nivolumab
Xiaoying, 96446688
+versus+Sorafenib+as+FirstLine+Treatment+in+Patients+with+Ad
vanced+Hepatocellular+Carcinoma&ra
nk=1
https://clinicaltrials.gov/ct2/show/NCT
02519348?term=A+Study+of+Safety%2
C+Tolerability%2C+and+Clinical+Activit
y+of+MEDI4736+and+Tremelimumab+ Elaine, 90887254
Administered+as+Monotherapy+and+i
n+Combination+to+Subjects+with&ran
k=1
1st line
A Randomized, Multi-center Phase III Study of Nivolumab
versus Sorafenib as First-Line Treatment in Patients with
Advanced Hepatocellular Carcinoma
CHILD-PUGH A, has
histological/cytological
diagnosis of HCC, ECOG 0-1
Dr. Akhil Chopra
2nd Line and above
[projected SIV in April] A Study of Safety, Tolerability, and
Clinical Activity of MEDI4736 and Tremelimumab
Administered as Monotherapy and in Combination to
Subjects with Unresectable Hepatocellular Carcinoma
confirmed diagnosis of
unresectable HCC; must have
progressed, refused or
intolerant to Sorafenib
Dr. Akhil Chopra
Main Criteria
Study title
Specification
Up to 3rd line
A Phase 3 Randomized, Placebo-Controlled Trial of
Carboplatin and Paclitaxel With or Without the PARP
Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic
or Locally Advanced Unresectable BRCA-Associated Breast
Cancer
Her 2 negative, BRCA
mutated, Failed Maximum 2
lines of chemotherapy
3rd line or more
A Study of Neratinib plus Capecitabine versus Lapatinib plus
Her 2 positive. Must have
Capecitabine in patients with HER2+ metastatic breast
failed 2 lines of HER 2 directed Dr. Lavina Bharwani
cancer who have received two or more prior HER2-directed
regimens.
regimens in the metastatic setting
http://www.clinicaltrials.gov/ct2/show
/NCT01808573?term=lapatinib+plus&r Elaine, 90887254
ank=5
1st line
A multicenter, randomized, double‑blind Phase 3 study of
Palbociclib (Oral CDK 4/6 inhibitor) plus letrozole versus
placebo plus letrozole for the treatment of previously
untreated east Asian postmenopausal women with ER (+),
HER2 (‑) advanced breast cancer [A5481027]
https://clinicaltrials.gov/ct2/show/NCT
Samantha, 83882481
02297438?term=Palbociclib&rank=29
Breast Cancer
SC, contact
Dr. Chia Yee Hong
postmenopausal, ER (+), Her 2
Dr. Chia Yee Hong
(-)
https://clinicaltrials.gov/ct2/show/NCT
Xiaoying, 96446688
02163694?term=Veliparib&rank=20
2nd and 3rd line
[SIV 6 Apr 2016] A Randomized Open-Label Phase III Study
of Single Agent Pembrolizumab versus Treatment of
Physician’s Choice Monotherapy for Metastatic Triple
Negative Breast Cancer (mTNBC)
Disease progression; previous
tx with one or two systemic
treatment; biopsy for PD-L1
positive status, ECOG 0-1
Dr Lavina Bharwani
https://clinicaltrials.gov/ct2/show/NCT
02555657?term=pembrolizumab+phys Samantha, 83882481
ician%27s+choice&rank=2
Lung cancer
3rd line or more
1st line
2nd or 3rd line
A Phase III, Open label, Randomised, Multi-centre,
International Study of MEDI4736, given as monotherapy or
in combination with Tremelimumab determined by PD-L1
expression versus Standard of Care in Patients with Locally EGFR and ALK negative, failed
Dr Akhil Chopra
Advanced or Metastatic Non-Small Cell Lung Cancer (Stage at least 2 lines of treatment
IIIB-IV) Who Have Received at Least Two Prior Systemic
including platinum
Treatment Regimens Including One Platinum-based
Chemotherapy Regimen and Do Not Have Known EGFR TK
Activating Mutations or ALK Rearrangements (ARCTIC)
https://clinicaltrials.gov/ct2/show/NCT
02352948?term=MEDI4736+%28ARCTI Elaine, 90887254
C%29&rank=1
A Phase 2, multicenter, randomized, double-blind study of
ficlatuzumab plus erlotinib versus placebo plus erlotinib in
subjects who have previously untreated metastatic, EGFRmutated non-small cell lung cancer (NCSLC) and BDX004
Poor Label
Prof. Alex Chang
https://clinicaltrials.gov/ct2/show/NCT
Elaine, 90887254
02318368?term=ficlatuzumab&rank=4
Dr Akhil Chopra
https://clinicaltrials.gov/ct2/show/NCT
02191891?term=BI+836845+EGFR&ra Ruth, 96421767
nk=1
EGFR positive, BDX004 Poor
label (blood draw)
A phase 1b open-label clinical trial of once daily oral
treatment of afatinib plus weekly intraveneous infusion of
BI 836845 in patients with EGFR mutant non-small cell lung Fail TKI, T790M negative.
cancer with progression following prior EGFR tyrosine
kinase inhibitors.
1st line
[SIV 30 Mar 2016] An Open-label, Randomized Phase 3
Efficacy Study of ASP8273 vs. Erlotinib or Gefitinib in Firstline Treatment of Patients with Stage IIIB/IV Non-small Cell
Lung Cancer Tumors with EGFR Activating Mutations
(SOLAR Study)
EGFR+, ECOG 0-2,
Histologically confirmed Stage
IIIB/IV adenocarcinoma NSCLC
Dr Akhil Chopra
Subjects with mixed histology
are eligible if adenocarcinoma
is the predominant histology
https://clinicaltrials.gov/ct2/show/NCT
02588261?term=An+Openlabel%2C+Randomized+Phase+3+Effic Belinda, 81025447
acy+Study+of+ASP8273+vs.+Erlotinib+
or+Gefitinib&rank=1
1st line
[projected SIV in April] Protocol: A Phase III, open-label,
multicenter trial of avelumab (MSB0010718C) versus
platinum based doublet as a first line treatment of
recurrent or Stage IV PD L1+ non small cell lung cancer
EGFR and ALK (-), PD-L1
positive, ECOG 0-1, measurable Dr Akhil Chopra
lesion
https://clinicaltrials.gov/ct2/show/NCT
Siti Maryam, 96192498
02576574?term=avelumab&rank=10
MEDI4736 in combination with tremelimumab, MEDI4736
monotherapy, and tremelimumab monotherapy will be safe
and demonstrate clinical activity in subjects with metastatic
or recurrent gastric or gastroesophageal junction (GEJ)
adenocarcinoma.
Her 2 negative, Refractory to
platimnum or
Fluoropyrimidine based
chemotherapy
https://clinicaltrials.gov/ct2/show/NCT
02340975?term=MEDI4736+monother Belinda, 81025447
apy%2C+and+tremelimumab&rank=1
Gastric Cancer
2nd and 3rd line
Dr. Alex Chang
Lymphoma
3rd line
A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMSFollicular Lymphoma
936558) in Subjects with Relapsed or Refractory Follicular
Lymphoma (FL) [CA209-140]
Dr. Akhil Chopra
https://clinicaltrials.gov/ct2/show/NCT
02038946?term=Lymphoma+%28FL%2 Belinda, 81025447
9+Nivolumab&rank=1
[re-opened, 2 slots available] Multicenter Phase II Study of
Nivolumab in Previously Treated Patients with Recurrent
and Metastatic Nasopharyngeal Carcinoma
non-keratinizing
nasopharyngeal carcinoma
Dr. Akhil Chopra
https://clinicaltrials.gov/ct2/show/NCT
02339558?term=Nivolumab+Nasophar Samantha, 83882481
yngeal&rank=1
A Multicentre, Randomized, Open-Label, Phase III Clinical
Trial Of Gemcitabine And Carboplatin Followed By EpsteinBarr Virus-Specific Autologous Cytotoxic T Lymphocytes
Versus Gemcitabine And Carboplatin As First Line
Treatment For Advanced Nasopharyngeal Carcinoma
Patients
Metastatic or locally recurrent
EBV positive, non-keratinizing
Dr. Akhil Chopra
and/or undifferentiated NPC
with measurable disease
https://clinicaltrials.gov/show/NCT025
Xiaoying, 96446688
78641
Castration-Resistant, failed at
least 12 weeks of Docetaxel
and abiraterone.
https://clinicaltrials.gov/ct2/show/NCT
02204072?term=BI+836845+Enzaluta
mide&rank=1
Siti Maryam, 96192498
NPC
2nd and above
1st line NPC
Prostate Cancer
3rd line
A Phase Ib/II, Multicentre, Open Label, Randomised Study
of BI 836845 in Combination With Enzalutamide, versus
Enzalutamide alone, in Metastatic Castration-Resistant
Prostate Cancer (CRPC) Following Disease Progression on
Dr. Akhil Chopra